SG11201705693XA - Universal killer t-cell - Google Patents

Universal killer t-cell

Info

Publication number
SG11201705693XA
SG11201705693XA SG11201705693XA SG11201705693XA SG11201705693XA SG 11201705693X A SG11201705693X A SG 11201705693XA SG 11201705693X A SG11201705693X A SG 11201705693XA SG 11201705693X A SG11201705693X A SG 11201705693XA SG 11201705693X A SG11201705693X A SG 11201705693XA
Authority
SG
Singapore
Prior art keywords
killer
universal
cell
universal killer
Prior art date
Application number
SG11201705693XA
Inventor
Sébastien Wälchli
Else Marit Inderberg Suso
Gustav Gaudernack
Gunnar Kvalheim
Original Assignee
Univ Oslo Hf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oslo Hf filed Critical Univ Oslo Hf
Publication of SG11201705693XA publication Critical patent/SG11201705693XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46443—Growth factors
    • A61K39/464434—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464457—Telomerase or [telomerase reverse transcriptase [TERT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464491—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11201705693XA 2015-01-23 2016-01-22 Universal killer t-cell SG11201705693XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1501175.2A GB201501175D0 (en) 2015-01-23 2015-01-23 A universal T-cell for personalised medicine
PCT/EP2016/051344 WO2016116601A1 (en) 2015-01-23 2016-01-22 Universal killer t-cell

Publications (1)

Publication Number Publication Date
SG11201705693XA true SG11201705693XA (en) 2017-08-30

Family

ID=52673865

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201705693XA SG11201705693XA (en) 2015-01-23 2016-01-22 Universal killer t-cell

Country Status (17)

Country Link
US (2) US11155786B2 (en)
EP (2) EP4095239A1 (en)
JP (1) JP6899333B2 (en)
KR (1) KR102479118B1 (en)
CN (1) CN107250351A (en)
AU (2) AU2016208475B2 (en)
CA (1) CA2973924C (en)
DK (1) DK3247791T3 (en)
EA (1) EA201791381A1 (en)
ES (1) ES2922231T3 (en)
GB (1) GB201501175D0 (en)
IL (1) IL253464B (en)
MX (1) MX2017009459A (en)
PL (1) PL3247791T3 (en)
PT (1) PT3247791T (en)
SG (1) SG11201705693XA (en)
WO (1) WO2016116601A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2986254A1 (en) 2015-05-18 2016-11-24 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
US20190134095A1 (en) * 2016-05-02 2019-05-09 Cerus Corporation Compositions and methods for improved nk cell therapies
CA3032498A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
CN109689686B (en) 2016-10-07 2020-08-25 T细胞受体治疗公司 Compositions and methods for T cell receptor weight programming using fusion proteins
US11851491B2 (en) 2016-11-22 2023-12-26 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
US20190358263A1 (en) 2016-12-07 2019-11-28 Oslo Universitetssykehus Hf Compositions and Methods for Cell Therapy
US11752172B2 (en) 2017-01-04 2023-09-12 Nova Southeastern University Natural killer (NK) cells expressing an antigen-specific functional T cell receptor (TCR) complex, methods for production thereof, and methods for therapeutic use thereof
EP3844499A1 (en) * 2018-08-31 2021-07-07 Invectys Sa Method to assess car functionality
JP6977969B2 (en) * 2019-03-22 2021-12-08 株式会社ガイアバイオメディシン Immune cell donation system
EP3750547A1 (en) 2019-06-13 2020-12-16 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Modified nk-92 cells, and therapeutic and diagnostic uses thereof
CN111662871A (en) * 2020-06-11 2020-09-15 福建医科大学孟超肝胆医院(福州市传染病医院) Aptamer functionalized NK (Natural killer) cell and preparation and application thereof
BR112023005318A2 (en) 2020-09-24 2023-04-25 Medigene Immunotherapies Gmbh PRAME-SPECIFIC T-CELL RECEPTORS AND USE THEREOF
TW202233831A (en) * 2020-11-03 2022-09-01 中國大陸商杭州啟函生物科技有限公司 Systems and methods for enhanced immunotherapies
GB202017873D0 (en) 2020-11-12 2020-12-30 Olso Unversitetssykehus Hf Method of determining DLBCL prognosis
KR20220160479A (en) * 2021-05-27 2022-12-06 (주)에스엠티바이오 Natural killer cells for treating neuroendocrine tumor
CN118215498A (en) 2021-09-21 2024-06-18 奥斯陆大学医院Hf Binding proteins for terminal deoxynucleotidyl transferase (TdT)
TW202325844A (en) * 2021-11-03 2023-07-01 中國大陸商杭州啟函生物科技有限公司 Systems and methods for enhanced immunotherapies
WO2024020537A2 (en) * 2022-07-22 2024-01-25 Board Of Regents, The University Of Texas System Cd3-expressing natural killer cells with enhanced function for adoptive immunotherapy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124251A (en) 1990-01-31 1992-06-23 Becton, Dickinson And Company CD3 ζ co-associated complex on CD16- NK cells
DE69834257T2 (en) 1997-04-30 2007-01-04 Klingemann, Hans NATURAL KILLER CELL LINES AND METHOD FOR THEIR USE
IL127142A0 (en) 1998-11-19 1999-09-22 Yeda Res & Dev Immune cells having predefined biological specificity
AU2002351239A1 (en) 2001-12-04 2003-06-17 Dana-Farber Cancer Institute, Inc. Antibody to latent membrane proteins and uses thereof
CA3052445C (en) * 2004-07-10 2023-08-22 Kerry S. Campbell Genetically modified human natural killer cell lines
WO2006050270A2 (en) * 2004-11-02 2006-05-11 The Government Of The United States Of America As Represented By The Secretary Department Of Health & Human Services Compositions and methods for treating hyperproliferative disorders
US8518697B2 (en) 2006-04-04 2013-08-27 Washington University Single chain trimers and uses therefor
CN101631138A (en) 2008-07-18 2010-01-20 深圳富泰宏精密工业有限公司 Personal information agent system and personal information agent method
WO2010088160A1 (en) * 2009-01-28 2010-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
DK2817620T3 (en) * 2012-02-22 2016-09-05 Verik Bio Inc IMMUNTERY TREATMENT SYSTEM FOR TUMOR FORMATION AND PROGRESSION
US11471486B2 (en) 2012-09-04 2022-10-18 Inven2 As Selective and controlled expansion of educated NK cells
WO2014117121A1 (en) 2013-01-28 2014-07-31 St. Jude Children's Research Hospital, Inc. A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
JP2016511636A (en) 2013-02-04 2016-04-21 ロジャー ウィリアムズ メディカル センターＲｏｇｅｒ Ｗｉｌｌｉａｍｓ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ Methods and compositions for treating gastrointestinal stromal tumors (GIST)
JP6425301B2 (en) 2014-05-29 2018-11-21 国立大学法人富山大学 NK cell line for evaluating the cytotoxic activity-inducing ability of TCR, and method for producing the same
WO2015193411A1 (en) 2014-06-18 2015-12-23 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Car-expressing nk-92 cells as cell therapeutic agents
US20170274014A1 (en) * 2014-07-21 2017-09-28 Jennifer Brogdon Combinations of low, immune enhancing, doses of mtor inhibitors and cars

Also Published As

Publication number Publication date
WO2016116601A1 (en) 2016-07-28
CA2973924A1 (en) 2016-07-28
KR20170121178A (en) 2017-11-01
JP2018512047A (en) 2018-05-10
KR102479118B1 (en) 2022-12-16
AU2016208475B2 (en) 2021-10-14
US20220127574A1 (en) 2022-04-28
EP3247791A1 (en) 2017-11-29
US20180010097A1 (en) 2018-01-11
EP4095239A1 (en) 2022-11-30
IL253464A0 (en) 2017-09-28
JP6899333B2 (en) 2021-07-07
US11155786B2 (en) 2021-10-26
AU2016208475A1 (en) 2017-08-03
EA201791381A1 (en) 2018-02-28
CA2973924C (en) 2024-06-04
PT3247791T (en) 2022-07-20
NZ733855A (en) 2023-10-27
DK3247791T3 (en) 2022-07-11
PL3247791T3 (en) 2022-09-05
ES2922231T3 (en) 2022-09-12
AU2022200126A1 (en) 2022-02-10
EP3247791B1 (en) 2022-05-04
GB201501175D0 (en) 2015-03-11
IL253464B (en) 2022-04-01
MX2017009459A (en) 2018-04-11
BR112017015631A2 (en) 2018-03-13
CN107250351A (en) 2017-10-13

Similar Documents

Publication Publication Date Title
IL253464A0 (en) Universal killer t-cell
HK1226232A1 (en) Universal speaker
HK1247061A1 (en) Improved vertical-slide clothes-hanging device
PL2987710T3 (en) Universal support
EP3277014A4 (en) Device
EP3269467B8 (en) Form-rolling device
ZA201605643B (en) Jumper insulator
EP3276859A4 (en) Device
GB201415044D0 (en) Clamp
EP3253103A4 (en) Device
RS58408B1 (en) Clamp
GB201509862D0 (en) Novel device
GB201501692D0 (en) Clutch Apparatus
GB201419210D0 (en) Clamp assembly
GB201406428D0 (en) Clamp
TWM534285U (en) Selfie clamp structure allowing universal combination
PL3025577T3 (en) Universal rakes
GB201415964D0 (en) Driveshaft assembly
EP3397889C0 (en) Connection device
GB201417275D0 (en) Tripod Portion
GB201517899D0 (en) Novel device
AU365067S (en) Aspirator
GB201515354D0 (en) Novel Device
GB201519111D0 (en) Handtool
GB201519110D0 (en) Handtool